Alfuzosin
- Generic Name
- Alfuzosin
- Brand Names
- Uroxatral, Xatral
- Drug Type
- Small Molecule
- Chemical Formula
- C19H27N5O4
- CAS Number
- 81403-80-7
- Unique Ingredient Identifier
- 90347YTW5F
- Background
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic b...
- Indication
Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH)
- Associated Therapies
- -
Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 30
- Registration Number
- NCT02977832
- Locations
- 🇮🇹
Urology Department Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 97
- Registration Number
- NCT02266537
Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 74
- Registration Number
- NCT01834729
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms
- Conditions
- Interventions
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Chesapeake Urology Research Associates
- Target Recruit Count
- 74
- Registration Number
- NCT00893113
- Locations
- 🇺🇸
Chesapeake Urology Research Associates, Towson, Maryland, United States
Evaluation of Symptom-specific Goal Achievement
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 130
- Registration Number
- NCT00836823
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Ulsan College of Medicine, Seoul, Korea, Republic of
Alfuzosin for Medical Expulsion Therapy of Ureteral Stones
- Conditions
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- United States Naval Medical Center, San Diego
- Target Recruit Count
- 240
- Registration Number
- NCT00713739
- Locations
- 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States
The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 232
- Registration Number
- NCT00696761
Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)
- Conditions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 20
- Registration Number
- NCT00688948
- Locations
- 🇨🇦
QE II Health Science Centre, Halifax Infirmary, Halifax, Nova Scotia, Canada
Once Daily Given Alfuzosin in the Treatment of BPH
- Conditions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00637715
- Locations
- 🇭🇺
Sanofi-Aventis, Budapest, Hungary
Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT00576823
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
🇸🇬Sanofi-Aventis Aministrative Office, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.